Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation
Introduction Prostate cancer (PC) is the most frequently diagnosed non-cutaneous cancer and the second most common cause of cancer-related death in men in the United States.1 Patients with metastatic, castration-resistant PC (mCRPC) experience significant …